Clinical trial
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous…
NCT00490529 · Ronald Levy, Other · Completed
Key facts
| NCT number | NCT00490529 |
|---|---|
| Title | Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL |
| Official title | Phase 1-2 Study of a CpG-Activated Whole Cell Vaccine Followed by Autologous "Immunotransplant" for Mantle Cell Lymphoma |
| Lead sponsor | Ronald Levy, Other |
| Collaborators | National Institutes of Health (NIH) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Mantle-Cell |
| Intervention type | Biological, Drug, Procedure |
| Interventions | CpG-MCL vaccine, PF-3512676, Vaccine-primed T-cells, Autologous hematopoietic stem cell transplant (HSCT), Rituximab, Standard induction chemotherapy, Cyclophosphamide, Filgrastim |
| Enrollment | 59 |
| Start date | Aug 1, 2009 |
| Primary completion | Dec 14, 2017 |
| Completion | Dec 14, 2017 |
| First posted | Jun 22, 2007 |
| Last update posted | Jan 13, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: